Today: 7 February 2026
Subscribe
Browse Category

Biotech Industry News 24 December 2025 - 9 January 2026

Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

New York, January 9, 2026, 17:15 ET — After-hours Revolution Medicines shares jumped 10.7% to $118.64 in after-hours trading on Friday, after the Financial Times reported Merck was in advanced talks to buy the cancer-drug developer for $28 billion to $32 billion. The stock swung between $109.88 and $125.79 in the session on volume of about 20.6 million shares. (Financial Times) The report lands as healthcare executives and bankers head to San Francisco for the annual J.P. Morgan Healthcare Conference, a dealmaking magnet that often sets the tone for the year. “Deals … could have had more regulatory risk in
9 January 2026
·····
Regeneron stock pops on BofA double-upgrade as 2026 catalysts stack up

Regeneron stock pops on BofA double-upgrade as 2026 catalysts stack up

New York, Jan 7, 2026, 20:51 EST — Market closed Regeneron Pharmaceuticals shares climbed 4.6% on Wednesday after Bank of America upgraded the drugmaker to “Buy” from “Underperform” and raised its price objective to $860. Investing.com The call matters because Regeneron’s stock has been stuck in a tug-of-war: investors want proof the company can defend its eye-medicine franchise as rivals and copycat versions crowd the field, while newer products and pipeline shots sit further out. BofA wrote that earlier worries around the standard-dose version of Eylea have been priced in, and it is now leaning on a faster shift to
8 January 2026
·····
AbbVie circles Revolution Medicines in possible $20 billion-plus deal: WSJ, Bloomberg

AbbVie circles Revolution Medicines in possible $20 billion-plus deal: WSJ, Bloomberg

New York, Jan 7, 2026, 16:14 (EST) AbbVie (ABBV.N) is in advanced talks to buy cancer-drug developer Revolution Medicines (RVMD.O), the Wall Street Journal reported on Wednesday, citing people familiar with the matter. Revolution shares jumped nearly 30% after the report, while AbbVie rose more than 5%. https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-talks-buy-biotech-revolution-medicines-wsj-reports-2026-01-07/ For AbbVie, a takeover would also sharpen its push to add new growth drivers as its former blockbuster Humira faces steeper competition after patent protection ended. It would put AbbVie deeper into oncology at a time when big drugmakers are still paying up for late-stage cancer assets. https://www.wsj.com/business/deals/abbvie-near-deal-for-revolution-medicines-eca830a1 The Journal did not
7 January 2026
····
Legend Biotech stock hits a fresh 52-week low as biotech lags — JPMorgan update looms

Legend Biotech stock hits a fresh 52-week low as biotech lags — JPMorgan update looms

New York, January 5, 2026, 15:53 EST — Regular session Legend Biotech Corp (LEGN) shares fell 4.7% to $20.49 on Monday, after touching $20.29 — a fresh 52-week low — in afternoon trading. The stock is about 55% below its 52-week high of $45.30. SoFi Money rotated into energy and bank stocks on Monday, lifting Wall Street’s main indexes, after a U.S. military strike captured Venezuelan President Nicolas Maduro. “Energy stocks are really benefiting from the expectation that President Trump is intending to send them in,” said Rob Haworth, senior investment strategist at U.S. Bank Wealth Management. Data showed U.S.
5 January 2026
····
Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

NEW YORK, January 1, 2026, 04:59 ET — Market closed Outlook Therapeutics, Inc. (Nasdaq: OTLK) shares fell sharply in after-hours trading on Dec. 31 after the U.S. Food and Drug Administration again declined to approve its ONS-5010/LYTENAVA (bevacizumab-vikg) filing for wet age-related macular degeneration. The stock closed down 15.51% at $1.58 and slid to $0.58 after hours. Nasdaq The decision is the third complete response letter the company has received on the application, following earlier FDA letters in August 2023 and August 2025, Ophthalmology Times reported. The drug is already authorized in the European Union and the UK and has
1 January 2026
····
Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

NEW YORK, January 1, 2026, 04:13 ET — Market closed Corcept Therapeutics Incorporated shares last closed down 50.4% at $34.80 on Wednesday. Yahoo Finance The selloff followed news that the U.S. drug regulator will not approve relacorilant in its current form for an expanded use tied to a rare hormonal disorder. The decision matters now because relacorilant was the company’s near-term bid to broaden its cortisol-modulation franchise beyond its existing product line, and investors had been bracing for a pivotal regulatory readout into year-end. A setback at the FDA can reset timelines and raise costs, forcing Wall Street to reprice
1 January 2026
·····
Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

NEW YORK, December 30, 2025, 15:16 ET — Regular session Travere Therapeutics Inc shares were down about 3.8% at $37.39 on Tuesday afternoon, extending losses after recent insider-trading disclosures. The stock traded between $37.27 and $39.20, with about 893,000 shares changing hands. (TVTX quote) The selling matters because it lands just weeks before a major regulatory milestone for the rare-disease drugmaker. Traders often react to clusters of insider sales — even when they are planned — as they reassess near-term positioning. Travere, based in San Diego, markets Filspari for a kidney disease called IgA nephropathy, and is seeking an expansion
30 December 2025
·····
Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

NEW YORK, December 30, 2025, 14:40 ET — Regular session Shares of Cogent Biosciences, Inc. fell 2.7% to $36.88 on Tuesday after the biotech said it submitted a New Drug Application to the U.S. Food and Drug Administration for its drug candidate bezuclastinib in nonadvanced systemic mastocytosis. Yahoo Finance An NDA is the formal request asking the FDA to review a drug for marketing approval, a key inflection point for development-stage biotechs with no products on the market. U.S. Food and Drug Administration Systemic mastocytosis is a rare disorder marked by abnormal accumulation and activation of mast cells — immune
30 December 2025
·····
ADMA Biologics stock slides nearly 4% as biotech weakens in thin year-end trade

ADMA Biologics stock slides nearly 4% as biotech weakens in thin year-end trade

NEW YORK, December 30, 2025, 13:35 ET — Regular session Shares of ADMA Biologics fell 3.7% to $18.40 in afternoon trading on Tuesday, a steeper drop than the broader biotech group. The SPDR S&P Biotech ETF was down about 1.3%. The pullback came as U.S. stocks steadied in holiday-thin trading ahead of minutes from the Federal Reserve’s December policy meeting, after the central bank delivered a 25-basis-point cut this month. Mark Hackett, chief market strategist at Nationwide, described recent positioning as “a healthy rebalancing of allocations.” Reuters Biotechnology shares were among the laggards, with the NYSE Arca Biotechnology Index down
30 December 2025
····
Merck & Co. (MRK) Enters 2026 in the Spotlight: BMO Upgrade to $130, FDA Fast-Track Vouchers and TrumpRx Pricing Deal Reframe the Post-Keytruda Story

Merck & Co. (MRK) Enters 2026 in the Spotlight: BMO Upgrade to $130, FDA Fast-Track Vouchers and TrumpRx Pricing Deal Reframe the Post-Keytruda Story

December 25, 2025 — Even with U.S. markets closed for Christmas Day, Merck & Co., Inc. (NYSE: MRK) is ending 2025 as one of the most-watched large-cap pharma names on Wall Street. The stock closed at $106.45 on Wednesday, Dec. 24, and commentary published today points to a six-day winning streak that has pushed investors back into “what’s next” mode: how Merck replaces Keytruda’s eventual loss of exclusivity while navigating a shifting U.S. drug-pricing backdrop. Nasdaq Below is a comprehensive, as-of-today roundup of the most consequential news, forecasts, and analyst analysis shaping Merck’s outlook heading into 2026—covering oncology, cardiovascular ambitions,
25 December 2025
····
Merck (MRK) Stock News on Dec. 25, 2025: BMO Lifts Target to $130 as FDA Fast-Track Vouchers and Keytruda Data Fuel Momentum

Merck (MRK) Stock News on Dec. 25, 2025: BMO Lifts Target to $130 as FDA Fast-Track Vouchers and Keytruda Data Fuel Momentum

December 25, 2025 — Merck & Co., Inc. (NYSE: MRK) is ending 2025 with something investors tend to enjoy: momentum with a story behind it. Even with U.S. markets closed for Christmas Day, Merck shares are in focus after a late-December climb that pushed the stock to fresh highs, helped along by a major Wall Street upgrade and a burst of pipeline and regulatory headlines. MarketBeat Below is what’s moving Merck stock, what the latest MRK forecasts imply for 2026, and the near-term catalysts (and risks) that could decide whether this rally is the start of a new chapter—or just
25 December 2025
·····
Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition

Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is ending 2025 with something investors in AI-driven biotech rarely get in the same month: fresh clinical momentum, a high-profile Wall Street upgrade, and renewed attention from Cathie Wood’s ARK funds—all playing out during a shortened Christmas Eve trading session. As of December 24, 2025, RXRX stock is trading around $4.37, up modestly on the day, with a market capitalization near $2.12 billion. That price level may look quiet at a glance—until you zoom out to the drivers behind the tape: REC-4881’s Phase 1b/2 TUPELO readout in familial adenomatous polyposis (FAP), J.P. Morgan’s upgrade, ARK’s
24 December 2025
····
1 2 3 4

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop